MaxCyte, Inc. (MXCT) stock
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value
$1.10−0.03 (-2.65%)
Close on Nov 11, 2026Market cap $113.53MP/E –Yield –
MaxCyte EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for MaxCyte
MaxCyte has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?